Secondary rise of albuminuria under AT1-receptor blockade - What is the potential role of aldosterone escape?

Nephrology Dialysis Transplantation

Volumn 22, Issue 1, 2007, Pages 5-8

  Rump, Lars Christian ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

ACE inhibition; Albuminuria; Aldosterone escape; Angiotensin II; AT1 receptor blockade

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HUMAN ALBUMIN; IRBESARTAN; LOSARTAN; MINERALOCORTICOID RECEPTOR; RAMIPRIL; SPIRONOLACTONE; VALSARTAN;

ADD ON THERAPY; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HORMONE SYNTHESIS; HUMAN; HYPERKALEMIA; KIDNEY FIBROSIS; NEPHRITIS; NONHUMAN; NOTE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT;

EID: 33846024058     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl549     Document Type: Note

References (34)

1. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005; 366: 2026-2033
2. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037
3. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927
4. Ibsen H, Olsen MH, Wachtell K et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595-600
5. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172
6. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-333
7. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068
8. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66: 1-9
9. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63(5): 1791-1800
10. Koppel H, Christ M, Yard BA, Bar PC, van der Woude FJ, Wehling M. Nongenomic effects of aldosterone on human renal cells. J Clin Endocrinol Metab 2003; 88: 1297-1302
11. Terada Y, Kobayashi T, Kuwana H et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 2005; 16: 2296-2305
12. Brown NJ, Nakamura S, Ma L et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227
13. Miyata K, Rahman M, Shokoji T et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912
14. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502
15. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263
16. Arima S, Kohagura K, Xu HL et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004; 43: 352-357
17. Mazak I, Fiebeler A, Muller DN et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004; 109: 2792-2800
18. Vonend O, Altenhenne C, Büchner NJ et al. A German family with glucocorticoid remediable aldosteronism. Nephrol Dial Transplant 2006
19. Rump LC. Advantages of Ang II receptor blockade over ACE inhibition with respect to suppression of sympathetic activity: Heartening news for the kidney? Nephrol Dial Transplant 1999; 14: 556-559
20. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064
21. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: Results from the Valsartan Heart Failure Trial. Circulation 2003; 108: 1306-1309
22. Folkeringa RJ, Pinto YM, Crijns HJ. Aldosterone levels after angiotensin receptor blocker treatment. Circulation 2004; 109: E182(author reply e182)
23. Spat A, Hunyady L. Control of aldosterone secretion: A model for convergence in cellular signaling pathways. Physiol Rev 2004; 84: 489-539
24. Campbell WB, Currie MG, Needleman P. Inhibition of aldosterone iosynthesis by atriopeptins in rat adrenal cells. Circ Res 1985; 57: 113-118
25. Naruse M, Tanabe A, Sato A et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in strokeprone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33
26. Funder JW. Cardiac synthesis of aldosterone: Going, going, gone? Endocrinology 2004; 145: 4793-4795
27. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005; 46: 584-590
28. Fiebeler A, Nussberger J, Shagdarsuren E et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111: 3087-3094
29. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926
30. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68
31. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51
32. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939
33. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49
34. Chrysostomou A, Pedagogos E, McGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262